How SkinJect's Microneedle Technology Could Transform the Treatment of Skin Cancer

Today, we are hosting Dr. Raza Bokhari, CEO at Medicus Pharma, to explore a breakthrough innovation in skin cancer treatment—SkinJect, a novel microneedle patch designed to eradicate cancerous cells non-invasively. By combining targeted drug delivery with an immunological response, SkinJect is shaping the future of dermatologic oncology. You can also follow this interview on LinkedIn by this link:>>>

Dr. Raza Bokhari will answer our questions about this innovative technology and its impact on skin cancer treatment. 

Some of the main topics in this interview include:

• Skin cancer is the most common cancer worldwide, and basal cell carcinoma makes up nearly 80% of cases. What challenges in current treatments inspired you to develop SkinJect?
• Mohs surgery is the standard treatment for basal cell carcinoma, but it can be invasive. How does SkinJect compare in terms of effectiveness, accessibility, and patient experience?
• SkinJect’s microneedle technology delivers doxorubicin directly into the lesion while triggering an immune response. Can you explain how this dual mechanism contributes to both tumor eradication and long-term recurrence prevention?
• Your Phase 1 trial demonstrated a strong safety and efficacy profile, with complete responses in several patients. What key endpoints are you evaluating in the ongoing Phase 2 SKNJCT-003 trial, and what makes this study design particularly robust?
• You have submitted a Type C meeting request with the FDA. What specific regulatory considerations or expedited pathways are you pursuing to accelerate SkinJect’s approval?

About Author: Hüseyin Kandemir

As a medical journalist with over 20 years of experience, I have served as an Editor and Reporter for various magazines, newspapers, and online broadcasting platforms, consistently demonstrating a strong commitment to excellence in journalism. My specialization includes medical science, digital health, AI for health, data science, and biotechnology.